Biologics are medicines taken by IV or self-injection and are made up of large protein molecules derived from living cells. There are now two versions of biologics: “originators” and “biosimilars.”

A biosimilar biologic enters the market after an originator biologic patent expires, just like a small molecule generic medication can when the brand name medication’s patent expires. And just the way generic medications are much lower in price compared to their original versions, so too are biosimilars.

In this video, Arthritis Consumer Experts' President, Cheryl Koehn looks at how a biosimilar has similar effectiveness, safety, immunogenicity profile and quality, and delivers the same therapeutic benefits to patients as its originator.

To learn more about biosimilars, click on the video.